CN113366014B - 经修饰的gip肽类似物 - Google Patents

经修饰的gip肽类似物

Info

Publication number
CN113366014B
CN113366014B CN201980090373.3A CN201980090373A CN113366014B CN 113366014 B CN113366014 B CN 113366014B CN 201980090373 A CN201980090373 A CN 201980090373A CN 113366014 B CN113366014 B CN 113366014B
Authority
CN
China
Prior art keywords
gip
seq
amino acid
glu
aeeac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980090373.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113366014A (zh
Inventor
A·H·斯帕雷-乌尔里希
B·B·西弗森
D·里伯
M·M·罗森基尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202511386362.3A priority Critical patent/CN121449720A/zh
Priority to CN202511386365.7A priority patent/CN121449721A/zh
Publication of CN113366014A publication Critical patent/CN113366014A/zh
Application granted granted Critical
Publication of CN113366014B publication Critical patent/CN113366014B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980090373.3A 2018-12-03 2019-12-03 经修饰的gip肽类似物 Active CN113366014B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202511386362.3A CN121449720A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物
CN202511386365.7A CN121449721A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18209896 2018-12-03
EP18209896.2 2018-12-03
EP19176739 2019-05-27
EP19176739.1 2019-05-27
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202511386365.7A Division CN121449721A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物
CN202511386362.3A Division CN121449720A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物

Publications (2)

Publication Number Publication Date
CN113366014A CN113366014A (zh) 2021-09-07
CN113366014B true CN113366014B (zh) 2025-10-21

Family

ID=68731999

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980090373.3A Active CN113366014B (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物
CN202511386365.7A Pending CN121449721A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物
CN202511386362.3A Pending CN121449720A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202511386365.7A Pending CN121449721A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物
CN202511386362.3A Pending CN121449720A (zh) 2018-12-03 2019-12-03 经修饰的gip肽类似物

Country Status (12)

Country Link
US (3) US12187773B2 (cg-RX-API-DMAC7.html)
EP (2) EP3891174A1 (cg-RX-API-DMAC7.html)
JP (1) JP7605747B2 (cg-RX-API-DMAC7.html)
KR (2) KR102906485B1 (cg-RX-API-DMAC7.html)
CN (3) CN113366014B (cg-RX-API-DMAC7.html)
AU (2) AU2019391300B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121043A1 (cg-RX-API-DMAC7.html)
IL (1) IL283385A (cg-RX-API-DMAC7.html)
MX (1) MX2021006505A (cg-RX-API-DMAC7.html)
SG (1) SG11202105586YA (cg-RX-API-DMAC7.html)
WO (2) WO2020115049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122520749A (zh) * 2019-12-03 2026-08-07 安泰博医药 优化的gip肽类似物
WO2022007809A1 (zh) * 2020-07-06 2022-01-13 鸿绪生物医药科技(北京)有限公司 新型多肽制剂及其治疗用途
AU2021304762B2 (en) * 2020-07-06 2024-05-02 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic use thereof
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
MX2023014740A (es) * 2021-06-10 2024-03-13 Antag Therapeutics Aps Tratamiento de la obesidad y trastornos relacionados con la obesidad.
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
CN117402219B (zh) 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
CN116120425A (zh) * 2022-12-27 2023-05-16 南京赛诺生物技术有限公司 一种glp-1/gip受体双重激动剂及其应用
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
AU2024224775A1 (en) * 2023-02-24 2025-10-09 Ip2Ipo Innovations Limited Compounds
WO2024209050A1 (en) * 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086769A2 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
WO2016034186A1 (en) * 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5745335A (en) 1996-06-27 1998-04-28 Gennum Corporation Multi-layer film capacitor structures and method
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
JP3270761B2 (ja) 1998-01-30 2002-04-02 ノボ ノルディスク アクティーゼルスカブ 注射器
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
ATE272650T1 (de) 1999-03-29 2004-08-15 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
ATE347764T1 (de) 2001-09-21 2006-12-15 Koninkl Philips Electronics Nv Gibt es kein spezifisches kontrollmodul? benutzen sie eines das weniger spezifisch ist
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
CA2732949C (en) 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
KR20130133103A (ko) 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체
CA2733005C (en) 2008-08-07 2016-09-27 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
KR102002783B1 (ko) * 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
US10774127B2 (en) 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
EP3556399A1 (en) * 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
WO2018124011A1 (ja) 2016-12-26 2018-07-05 花王株式会社 運動調節機能向上剤
US20190330332A1 (en) 2016-12-26 2019-10-31 Kao Corporation Hypothermia Ameliorating Agent
EP3569248B1 (en) 2016-12-26 2023-12-06 Kao Corporation Gip inhibitors for improving cognitive function
US11572399B2 (en) * 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086769A2 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
WO2016034186A1 (en) * 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice;V. Pathak等;《Molecular and Cellular Endocrinology》;第401卷;第120-129页 *
V. Pathak等.Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.《Molecular and Cellular Endocrinology》.2015,第401卷第120-129页. *

Also Published As

Publication number Publication date
MX2021006505A (es) 2021-10-01
KR102906485B1 (ko) 2025-12-31
SG11202105586YA (en) 2021-06-29
JP7605747B2 (ja) 2024-12-24
AU2025237957A1 (en) 2025-10-16
EP3891174A1 (en) 2021-10-13
KR20260011770A (ko) 2026-01-23
US20250376499A1 (en) 2025-12-11
US12297250B2 (en) 2025-05-13
US20220025010A1 (en) 2022-01-27
IL283385A (en) 2021-07-29
CA3121043A1 (en) 2020-06-11
WO2020115048A1 (en) 2020-06-11
AU2019391300B2 (en) 2025-06-26
CN121449721A (zh) 2026-02-03
CN113366014A (zh) 2021-09-07
AU2019391300A1 (en) 2021-07-01
EP3891173A1 (en) 2021-10-13
US20220298218A1 (en) 2022-09-22
JP2022509568A (ja) 2022-01-20
US12187773B2 (en) 2025-01-07
CN121449720A (zh) 2026-02-03
WO2020115049A1 (en) 2020-06-11
BR112021010447A2 (pt) 2021-08-24
KR20210102911A (ko) 2021-08-20

Similar Documents

Publication Publication Date Title
US20250376499A1 (en) Modified gip peptide analogues
CN110691788B (zh) 长效gip肽类似物
CN114761420B (zh) 优化的gip肽类似物
CN108135981A (zh) 胰高血糖素受体激动剂
KR20150003910A (ko) Gip-glp-1 이원 작용제 화합물 및 방법
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
CA3064510C (en) Long-acting gip peptide analogues

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant